Tuberculosis (TB) suspect is any one who has signs or symptoms suggestive of TB (eg >2 weeks productive cough).
Definite TB is considered in patients with culture or molecular line probe assay positive for Mycobacterium tuberculosis, or in patients with at least 1 sputum smear positive for acid-fast bacilli.
TB cases are also classified based on the disease anatomical site, bacteriological results (including drug resistance), previous treatment history and patient's HIV status.
Pulmonary TB is a case of TB that involves the lung parenchyma.
Miliary TB is considered as PTB since lung lesions are also seen.
TB in the pleural effusion, mediastinal and/or hilar lymph nodes with no evidence of abnormalities in the chest x-ray are considered extrapulmonary TB.
Patients presenting with both PTB and extrapulmonary TB are classified as a case of PTB.
Four months of daily rifampicin is safer than 9 months of daily isoniazid when it comes to treating latent tuberculosis (TB) infection, according to a post hoc safety analysis on pooled data from two randomized studies* — thus rendering the ambitious goal by the WHO to treat 30 million patients by 2022 possible.
A recently published analysis of the world’s largest genome-wide association study (GWAS) of lung cancer among female never-smokers found a set of tuberculosis (TB)-related genes associated with lung adenocarcinoma in Asian women.
A shorter regimen comprising a seven-drug cocktail which included high-dose moxifloxacin for 9 months was noninferior to the WHO*-recommended long regimen of 20 months for treating rifampicin-resistant tuberculosis (TB), according to the STREAM** study, providing a feasible and lower-cost treatment option in resource-poor setting.
Use of a short regimen in the treatment of rifampin-resistant tuberculosis (TB) infection is noninferior to a long regimen in terms of efficacy and comparable with respect to safety, according to the results of the phase III STREAM* trial.
Metformin is the only medication among all types of antidiabetic therapy (ADT) and insulin therapies that lowers the risk of active tuberculosis (TB) in the type 2 diabetes mellitus (T2DM) population, a recent study has shown.
Dr Indumathi Venkatachalam, a consultant at the Department of Infectious Diseases, Singapore General Hospital, speaks to Roshini Claire Anthony on how GPs can help ensure early detection of tuberculosis (TB).
Treatment with metformin appears to significantly reduce tuberculosis (TB) risk in patients with type 2 diabetes mellitus, a study has found. However, this protective effect diminishes with age and is absent among those with metabolic disorders.
Higher doses of rifampin result in more rapid sputum sterilization and similar toxicity, a study has shown. These findings support the investigation of increased rifampin doses to shorten tuberculosis treatment.
Gefapixant, a first-in-class non-narcotic, oral P2X3 receptor antagonist, significantly reduces cough frequency in patients with refractory or unexplained chronic cough, according to two COUGH* studies presented at ERS 2020.
Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.
Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.